about
The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury.Spatio-temporal deleted in colorectal cancer (DCC) and netrin-1 expression in human foetal brain development.Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception.Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapyHead and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrencesAntibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomasBevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomasNetrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases.Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acidImmunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastasesDownstream effects of plectin mutations in epidermolysis bullosa simplex with muscular dystrophyBACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's diseaseMolecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.Cardiac period 2 in myocardial ischemia: clinical implications of a light dependent protein.FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.Autophagy-associated proteins BAG3 and p62 in testicular cancer.ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation.MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patientsATP synthase deficiency due to TMEM70 mutation leads to ultrastructural mitochondrial degeneration and is amenable to treatment.Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases.β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas.EGFL7 ligates αvβ3 integrin to enhance vessel formation.Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma."Two is not enough" - Impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma.EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
P50
Q30536373-4E34628F-2CAF-4063-B7D1-2EA77CEF562EQ33626908-97B699F2-9D63-40D0-952E-138137B26D00Q33861405-73800481-77BD-47A5-B4B1-AF8CEF447942Q33972116-69228485-B51D-4157-A9B2-F72B374E76C0Q34354547-1A935FC1-5B7E-42AC-9477-5937AD0E44DAQ34439193-907D431C-DB08-4CBA-BAD3-87C12F817FECQ34517339-77AC3D5F-EE13-4F3F-BB7C-01E20B79DF1DQ34807753-F6886D5C-A923-40E3-9352-A0A2413E1EA2Q35125199-B445A048-5027-448D-B429-900AC197D480Q35152103-A7F69EF0-A5EF-4C6C-BEBD-9875924B4ADCQ35636781-A1488A9F-60B6-44E6-9AE1-81680FE276CCQ35987408-1075CE3F-9519-4D93-9C67-E7A6D244F7B2Q36477818-EC0E9C1A-6D4A-4833-AACD-C2D67E1E96B5Q36493852-B903B0C6-6EB4-4395-875B-7FFBD279ACCDQ36562180-76DB7757-A623-458B-8A6A-A827190E45E9Q36842582-F208582F-DB1A-45FD-A6C9-FDA2D3EC9B35Q37057708-0915FE83-6E00-43F5-AB35-1E2A9467FBF9Q37362574-5B88A800-606B-43D8-A96C-A1DBF51D939EQ37579928-E621DB6B-B0EC-4FBE-A48D-850B954FC5E5Q38071849-285F687D-77BF-46D7-A930-A4685FDEFBAEQ38731367-E1F41F9A-78A2-4DF5-B55B-3EFBA191C62BQ38765219-BECEEDF6-1FD2-46BD-8AFF-2A8E2B73A077Q38808865-B752339B-560F-44BF-A56B-216DE9658A8BQ38814097-38986140-FABB-4D47-867D-BE5098F26E2EQ38913917-F3491CD2-2E3B-46EF-8CD9-1B0977F13E76Q40979569-9E0BD25B-15D9-4174-A829-3C3FE58A5C3DQ41228349-55D900B3-9DB1-4A23-8D53-9725BF9F799EQ41412889-23128C55-8106-4628-B8D6-5E8785CF7F63Q41772481-2998078F-1127-49B4-8583-E44DD9C65856Q41935281-3EBB8E02-E5F1-4E43-88E7-69C288DC9D5EQ41985110-7D84922A-0409-4B0E-878D-41338FF9D555Q44110826-06ED2422-0485-4668-8EBF-06CA54939DB4Q44135041-7F4CF053-B0B5-43D7-8178-D06A9DF72493Q44741115-CE87AD32-B372-4876-A193-AD6533A0E949Q46296960-3001EB04-7856-4069-AA0A-15A949172D89Q47167281-9311E94B-861C-4E21-B3A3-6804F79AE007Q47948966-1104E259-20FA-470D-8119-8215E97C03BBQ47997436-3BBE0DE7-4B3D-4760-B338-218C616B1C6DQ48014727-C579EC0F-2D47-407E-A7E7-39CD33DF52AEQ48015053-793CA285-67D9-42A2-9916-A7161612680A
P50
description
German physician
@en
Saksamaa arst
@et
deutscher Arzt
@de
medic german
@ro
medico tedesco
@it
metge alemany
@ca
mjek gjerman
@sq
médecin allemand
@fr
médico alemán
@es
médico alemán
@gl
name
Patrick N. Harter
@ast
Patrick N. Harter
@de
Patrick N. Harter
@en
Patrick N. Harter
@fr
Patrick N. Harter
@nl
Patrick N. Harter
@sl
type
label
Patrick N. Harter
@ast
Patrick N. Harter
@de
Patrick N. Harter
@en
Patrick N. Harter
@fr
Patrick N. Harter
@nl
Patrick N. Harter
@sl
altLabel
Patrick Nikolaus Harter
@de
prefLabel
Patrick N. Harter
@ast
Patrick N. Harter
@de
Patrick N. Harter
@en
Patrick N. Harter
@fr
Patrick N. Harter
@nl
Patrick N. Harter
@sl
P214
P227
P106
P21
P214
P227
P31
P496
0000-0001-5530-6910
P569
1980-01-01T00:00:00Z
P735
P7859
viaf-80608453